1089 related articles for article (PubMed ID: 23218699)
1. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
Heier JS; Clark WL; Boyer DS; Brown DM; Vitti R; Berliner AJ; Kazmi H; Ma Y; Stemper B; Zeitz O; Sandbrink R; Haller JA
Ophthalmology; 2014 Jul; 121(7):1414-1420.e1. PubMed ID: 24679444
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
Korobelnik JF; Holz FG; Roider J; Ogura Y; Simader C; Schmidt-Erfurth U; Lorenz K; Honda M; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
Ophthalmology; 2014 Jan; 121(1):202-208. PubMed ID: 24084497
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.
Boyer D; Heier J; Brown DM; Clark WL; Vitti R; Berliner AJ; Groetzbach G; Zeitz O; Sandbrink R; Zhu X; Beckmann K; Haller JA
Ophthalmology; 2012 May; 119(5):1024-32. PubMed ID: 22440275
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
Campochiaro PA; Clark WL; Boyer DS; Heier JS; Brown DM; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Haller JA
Ophthalmology; 2015 Mar; 122(3):538-44. PubMed ID: 25315663
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
Ogura Y; Roider J; Korobelnik JF; Holz FG; Simader C; Schmidt-Erfurth U; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
Am J Ophthalmol; 2014 Nov; 158(5):1032-8. PubMed ID: 25068637
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
[TBL] [Abstract][Full Text] [Related]
11. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.
Gonzalez VH; Boyer DS; Schmidt-Erfurth U; Heier JS; Gordon C; Benz MS; Marcus DM; Sabates NR; Vitti R; Kazmi H; Berliner AJ; Soo Y; Zhu X; Moini H; Zeitz O; Sandbrink R; Do DV
Retina; 2015 Apr; 35(4):687-94. PubMed ID: 25621943
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study.
Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
Ophthalmology; 2012 Jun; 119(6):1184-9. PubMed ID: 22424833
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I
Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
[TBL] [Abstract][Full Text] [Related]
15. Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies.
Feltgen N; Ogura Y; Boscia F; Holz FG; Korobelnik JF; Brown DM; Heier JS; Stemper B; Rittenhouse KD; Asmus F; Ahlers C; Vitti R; Saroj N; Mitchell P
Ophthalmol Retina; 2019 Jul; 3(7):553-560. PubMed ID: 31277796
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
17. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.
Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
Ophthalmology; 2012 Dec; 119(12):2587-91. PubMed ID: 22902212
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
[TBL] [Abstract][Full Text] [Related]
19. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
Ruiz-Moreno JM
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
Brown DM; Campochiaro PA; Singh RP; Li Z; Gray S; Saroj N; Rundle AC; Rubio RG; Murahashi WY;
Ophthalmology; 2010 Jun; 117(6):1124-1133.e1. PubMed ID: 20381871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]